Document is current
Any future updates will be listed below
-
Authors
Scherer, Sandra D.
Riggio, Alessandra I.
Haroun, Fadi
DeRose, Yoko S.
Ekiz, H. Atakan
Fujita, Maihi
Toner, Jennifer
Zhao, Ling
Li, Zheqi
Oesterreich, Steffi
Samatar, Ahmed A.
Welm, Alana L. http://orcid.org/0000-0002-1412-1351
-
Funding
Funding for this research was provided by:
U.S. Department of Defense (W81XWH-12-1-0077)
National Institutes of Health (UL1TR002538)
National Cancer Institute (5P30CA042014)
Zentalis Pharmaceuticals
- License Information
-
More Information
Article History
Received: 27 May 2021
Accepted: 11 October 2021
First Online: 30 October 2021
Declarations
:
: Not applicable.
: Not applicable.
: ALW, SDS, YSD, or MF may receive financial compensation from tangible property licenses managed by the University of Utah if PDX models that they developed are licensed by a for-profit company. ALW received funding from Zentalis Pharmaceuticals, Inc. for a portion of this study. AAS is an employee of Zentalis Pharmaceuticals, Inc.
